X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (109) 109
adult (91) 91
male (89) 89
female (87) 87
middle aged (77) 77
index medicus (76) 76
infectious diseases (61) 61
hiv (57) 57
hiv infections - drug therapy (40) 40
aged (39) 39
treatment outcome (39) 39
immunology (36) 36
virology (31) 31
viral load (29) 29
human immunodeficiency virus--hiv (26) 26
hiv infections - virology (25) 25
young adult (25) 25
viruses (24) 24
antiretroviral therapy (23) 23
drug therapy, combination (23) 23
health aspects (23) 23
infection (23) 23
drug therapy (22) 22
therapy (22) 22
adolescent (21) 21
hepatitis (21) 21
hepatitis c (20) 20
infections (20) 20
aids (19) 19
hiv infection (19) 19
rna, viral - blood (19) 19
anti-hiv agents - therapeutic use (18) 18
europe (18) 18
research (18) 18
gastroenterology & hepatology (17) 17
hepacivirus - genetics (17) 17
hepatitis c virus (17) 17
hepatitis c, chronic - drug therapy (17) 17
hiv-1 - drug effects (17) 17
hiv-1 - genetics (17) 17
microbiology (17) 17
poland (17) 17
prevalence (17) 17
risk factors (17) 17
virus diseases (17) 17
antiviral agents - therapeutic use (16) 16
drug resistance (16) 16
analysis (15) 15
antiviral agents (15) 15
care and treatment (15) 15
cd4 lymphocyte count (15) 15
epidemiology (15) 15
medicine (15) 15
rna (15) 15
antiretroviral drugs (14) 14
hiv infections - epidemiology (14) 14
interferon (14) 14
patients (14) 14
poland - epidemiology (14) 14
research article (14) 14
ribavirin (14) 14
europe - epidemiology (13) 13
hiv patients (13) 13
interferon-alpha - therapeutic use (13) 13
mutation (13) 13
ribavirin - therapeutic use (13) 13
double-blind method (12) 12
genetic aspects (12) 12
hiv-1 (12) 12
infectious disease (12) 12
acquired immune deficiency syndrome--aids (11) 11
antiviral agents - administration & dosage (11) 11
drug resistance, viral (11) 11
gastroenterology and hepatology (11) 11
genotype (11) 11
highly active antiretroviral therapy (11) 11
hiv infections - transmission (11) 11
liver (11) 11
time factors (11) 11
abridged index medicus (10) 10
anti-hiv agents - pharmacology (10) 10
antiretroviral therapy, highly active (10) 10
disease transmission (10) 10
dosage and administration (10) 10
genotype & phenotype (10) 10
hcv (10) 10
hiv infections - immunology (10) 10
lamivudine (10) 10
liver diseases (10) 10
multidisciplinary sciences (10) 10
protease inhibitors (10) 10
ribonucleic acid--rna (10) 10
tenofovir (10) 10
aids/hiv (9) 9
antiviral agents - adverse effects (9) 9
cohort studies (9) 9
drug resistance, viral - genetics (9) 9
hepatitis b, chronic - drug therapy (9) 9
hepatology (9) 9
hospitals (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Retrovirology, ISSN 1742-4690, 01/2013, Volume 10, Issue 1, pp. 7 - 7
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2417 - 2428
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1429 - 1441
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 1, pp. 27 - 35
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2010, Volume 201, Issue 6, pp. 803 - 813
Background. The MERIT (M̄araviroc versus Ēfavir̄enz īn T̄reatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in... 
HIV/AIDS | Tropisms | RNA | HIV | Stock options | Response rates | Viruses | Infections | Post hoc | HIV 1 | Virology | INFECTIOUS DISEASES | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | LOPINAVIR-RITONAVIR | THERAPY | VIROLOGICAL FAILURE | RESISTANT HIV-1 | INHIBITOR | CORECEPTOR TROPISM | PLUS | Anti-HIV Agents - pharmacology | Lamivudine - administration & dosage | Cyclohexanes - pharmacology | Humans | Middle Aged | Drug Resistance, Viral | Male | Anti-HIV Agents - standards | Viral Load | Zidovudine - administration & dosage | Young Adult | Cyclohexanes - therapeutic use | Receptors, CCR5 - metabolism | HIV-1 - physiology | Adult | Female | Triazoles - standards | Viral Tropism | Drug Therapy, Combination | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Antiviral Agents - pharmacology | Double-Blind Method | HIV-1 - drug effects | Treatment Outcome | Anti-Retroviral Agents | Benzoxazines - standards | Benzoxazines - therapeutic use | Triazoles - pharmacology | Adolescent | Benzoxazines - pharmacology | Cyclohexanes - standards | HIV Infections - drug therapy | Aged | Drug Combinations | Maraviroc | Patient outcomes | Physiological aspects | Dosage and administration | Genetic aspects | Research | Drug therapy, Combination | Drug therapy | HIV infection | Efavirenz | Chemokines
Journal Article
Journal Article
Hepatology, ISSN 0270-9139, 12/2012, Volume 56, Issue 6, pp. 2039 - 2050
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 7, pp. 1669 - 1679.e3
Background & Aims Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir... 
Gastroenterology and Hepatology | Drug | Chronic Hepatitis C | DAA | PROMISE | ALPHA-2A | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | MANAGEMENT | CHRONIC HEPATITIS-C | PEGYLATED INTERFERON | BOCEPREVIR | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | ONCE-DAILY TMC435 | Recombinant Proteins - therapeutic use | Recurrence | Simeprevir | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | North America | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Time Factors | Hepatitis C - blood | Protease Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Double-Blind Method | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis C - diagnosis | Hepacivirus - enzymology | Sulfonamides - therapeutic use | Asia | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Hepacivirus - growth & development | Viral Nonstructural Proteins - metabolism | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Care and treatment | Proteases | Interferon alpha | Clinical trials | Product development | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Life Sciences
Journal Article